The years since PERSEPHONE was opened saw a number of important changes to the standard of care of early HER2-positive breast cancer, with non-anthracycline regimens (de-escalation) and double blockade/extended therapy (escalation), making PERSEPHONE harder to interpret.11 The gene discussed is ERBB2; the disease is breast carcinoma.